PolyPeptide Group AG Company Description

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally.

It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products.

The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services.

The company serves academic, pharmaceutical, and biotech companies. PolyPeptide Group AG was founded in 1952 and is headquartered in Baar, Switzerland.

PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.

PolyPeptide Group AG

Country	Switzerland
Founded	1952
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	1,440
CEO	Juan Gonzalez

Contact Details

Address: Neuhofstrasse 24 Baar, 6340 Switzerland
Phone	41 435 020 580
Website	polypeptide.com

Stock Details

Ticker Symbol	PPGN
Exchange	SIX Swiss Exchange
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	CH1110760852
SIC Code	8731

Key Executives

Name	Position
Juan Jose Gonzalez	Chief Executive Officer
Marc Augustin	Chief Financial Officer
Rene Vestergaard	Director of Corporate Finance
Olivier Ludemann-Hombourger	Director of Global Innovation and Technology
Michael Staheli	Head of Investor Relations and Corporate Communications
Christina Del Vecchio	Chief Legal Officer and Corporate Secretary
Andreas Liese	Corporate Compliance Manager
Trishul Shah MS	Interim Director Global Sales and Marketing
Monika Casanova	Chief Human Resources Officer
Christophe Chevalier	Head of Technical Department - Braine